以痘苗病毒天坛株为载体的表达单纯疱疹病毒Ⅰ型糖蛋白D的重组活疫苗的建立

从我国分离到的一株单纯疱疹病毒Ⅰ型（ＨＳＶ－１－１６８株）病毒基因组中,分离出含有糖蛋白Ｄ（ｇＤ）基因的１．２ｋｂ片段,插入带有痘苗病毒天坛株ＴＫ区的质粒ｐＪＳＢ１１７５Ｐ７．５ｋ启动子下游,转染无白血病鸡胚原代细胞,获得带有ＨＳＶ－１－１６８ｇＤ基因的重组痘苗病毒。此株重组病毒在感染细胞膜上表达ＨＳＶ－１－１６８ｇＤ糖蛋白抗原,能与特异性单克隆抗体反应。在感染细胞中表达的膜抗原经ＳＤＳ－ＰＡＧＥ分析,表达分子量为５４ｋＤ糖蛋白。用Ｓｏｕｔｈｅｒｎ杂交分析了重组病毒ＤＮＡ中特异的ｇＤ基因,对作为活疫苗的重组痘苗病毒株进行了一些微生物学活性、免疫原性和毒力等方面的研究。     

以痘苗病毒天坛株为载体的表达单纯疱疹病毒I型糖蛋白D的重组活疫苗…

从我国分离到的一株单纯疱疹病毒Ｉ型病毒基因组中,分离出含有糖蛋白Ｄ基因的１．２ｋｂ片估,插入带有痘苗病毒天坛株ＴＫ区的持粒ｐＪＳＢ１１７５Ｐ７．５ｋ启动子下游,转染无白血病鸡胚原供细胞,获得带有ＨＳＶ－１－１６８ｇＤ基因的重组痘苗病毒。此株重组病毒在感染细胞膜上表达ＨＳＶ－１－１６８ｇＤ糖蛋白抗原,能与特异性单克隆抗体反应。     

汉滩病毒糖蛋白G1G2和核蛋白NP在痘苗病毒天坛株中的联合表达

以汉滩病毒７６／１１８株Ｍ、Ｓ片段分别插入转南粒ＰＪＳＢ１１７５的Ｐ１１和Ｐ７．５启动子下游,构建成重组质粒ＰＪＳＢ１１７．５Ｓ。采用Ｌｉｐｏｆｅｃｔｉｎ转染针重组质粒分别与痘苗病毒天坛株ＴＫｖｖ和表达Ｓ片的重线痘苗病毒ＶＪＳＡ１１７５Ｓ进行共转染,免疫酶斑和蓝白筛法筛选并纯化,得到了重组病毒ＶＪＳＢ１１Ｍ５Ｓ。Ｂｕｄｒ的选择压力试验表明,外源基因确定插入在ＴＫ基因区;ＰＣＲ及打点杂交证实了两个片     

一株新的狂犬病重组痘苗病毒某些生物学性质的研究

对表达狂犬病毒糖蛋白的重组痘苗病毒ＶＶＭ１１ＫＲＧ株生物学性质进行了研究,该重组病毒的特点是：（１）糖蛋白基因插入到痘苗病毒天坛株基因组ＨｉｎｄⅢＭ片段中;（２）启动子为痘苗病毒天坛株Ｐ１１晚期启动子;（３）不含外源ｌａｃ基因。该重组病毒在ＣＶ－１细胞和鸡胚细胞上繁殖滴渡略高于另一株重组痘苗病毒ＶＶＴＫ１１ＫＲＧ,在鸡胚细胞中繁殖滴度第三天达到最高,在ＣＶ－１细胞中第二天达到最高。温度稳定性与天坛株相比没有明显改变。重组病毒在家兔皮内的毒力比亲本株（天坛株）低。间接免疫荧光和Ｗｅｓｔｅｒｎｂｌｏｔ都证明了狂犬病毒糖蛋白有良好的表达。通过Ｓｏｕｔｈｅｒｎｂｌｏｔ证实糖蛋白基因准确地插入到ＨｉｎｄⅢＭ片段中。重组痘苗病毒启动子与部分糖蛋白基因克隆到ｐＧＥＭ３ｚｆ（－）质粒上,对该段ＤＮＡ序列分析表明不会产生移码和融合蛋白,从而为该重组病毒的使用提供了明确的基因背景资料。     

我国单纯疱疹病毒I型168株糖蛋白D基因的克隆及其在痘苗病毒天坛…

将我国单纯疱疹病毒Ｉ型１６８株基因组ＤＮＡ中扩增出的糖蛋白Ｄ基因,插入痘苗病毒ｐ７．５启动子下游,使其在痘苗病毒天坛株表达,免疫荧光分析表明,产生的重组病毒糖蛋白Ｄ能被运到被重且病毒感染的１４３细胞表面表达,表达的产物经Ｗｅｓｔｅｎｂｌｏｔ鉴定为分子量约５０ｋＤ的多肽,Ｓｏｕｔｈｅｒｎｂｌｏｔ证明重组病毒基因组中整合有ＨＳＶ－１１６８株糖蛋白基因片段,重组病毒免疫家兔后,产生了高滴度的ＨＳＶ特异性     

我国单纯疱疹病毒Ⅰ型168株糖蛋白D基因的克隆及其在痘苗病毒天坛株中的表达

将我国单纯疮疹病毒Ⅰ型１６８株基因组ＤＮＡ中扩增出的糖蛋白Ｄ基因,插入痘苗病毒ｐ７．５启动子下游,使其在痘苗病毒天坛株表达。免疫荧光分析表明,产生的重组病毒糖蛋白Ｄ能被运到被重组病毒感染的１４３细胞表面表达,表达的产物经Ｗｅｓｔｅｍｂｌｏｔ鉴定为分子量约５０ｋＤ的多肽。Ｓｏｕｔｈｅｍｂｌｏｔ证明重组病毒基因组中整合有ＨＳＶ－１１６８株糖蛋白基因片段,重组病毒免疫家兔后,产生了高滴度的ＨＳＶ特异性中和抗体。     

表达人GM—CSF重组痘苗病毒抗肿瘤作用的实验研究

将ｈＧＭ－ＣＳＦｃＤＮＡ插入含有Ｐ１１ｋ及２５ｋ双向启动子的痘苗病毒载体ＰＪ１２０的Ｐ１１Ｋ启动子下游,而Ｐ２５Ｋ下游则为ＬａｃＺ基因,成表达质粒ｐＪ１２０／ＧＭ－ＣＳＦ。,以此质粒与痘苗病毒天坛株共转染ＴＫ－１４３细胞。在ＢＵdisplay status     

用pKKH质粒在大肠杆菌中表达HuIFN－β

应用ＤＮＡ重组技术,将ＨｕＩＦＮ－β基因插入到质粒ｐＫＫＨ的ｔａｃ启动子下游,转化大肠杆菌ＪＭ１０１和ＪＭ１０３,经ＩＰＴＧ诱导,表达ＨｕＩＦＮ－β,收集并裂解细菌,用Ｗｉｓｈ－ＶＳＶ系统细胞病变抑制法检测生物学活性为２．１８×１０８－８．７×１０８ＩＵ／Ｌ菌液。经初步纯化ＳＤＳ－ＰＡＧＥ电泳可见分子量为２０ＫＤ较纯的表达带。     

人精子膜蛋白片段在沙门氏菌中的表达——一种制备抗生育疫苗的途径

合成编码一种人精子膜蛋白ＹＷＫ－Ⅱ胞外区的一段多肽片段的双链寡核苷酸链,ＨＳＤ－２ａ。用平端连接的方法将其插入到沙门氏菌鞭毛基因ｆｌｉＣ（ｄ）的抗原表位ＩＶ高变区ＥｃｏＲＶ位点,构建了重组质粒ｐＬＳ４０８－Ｈ１。重组基因在鞭毛负性ａｒｏＡ基因缺失的无致病性沙门氏菌Ｓ．ｄｕｂｌｉｎ ＳＬ５９２８疫苗菌株中表达。经ＥＬＩＳＡ、电镜免疫胶体金法检测,表明ＨＳＤ－２ａ编码的多肽片段成功地在沙门氏菌鞭毛表面     

汉滩病毒A9株M基因片段在重组痘苗病毒中的表达及鉴定

为发展国产化肾综合征出血热（ＨＦＲＳ）病毒基因工程疫苗,选择了汉滩病毒Ａ９株Ｍ基因片段为目的基因,构建转染质粒ｐＪＳＢＡ９Ｍ。以携带Ｌａｃ基因的重组病毒为亲本,使表达载体ｐＪＳＢ－Ａ９Ｍ上的Ｍ片段与痘苗病毒内的Ｌａｃ基因重组,将Ｌａｃ置换成Ａ９Ｍ片段。用蓝白斑法筛选重组痘苗病毒,经ＰＣＲ扩增证实Ａ９Ｍ片段重组入痘苗病毒基因组内。重组痘苗病毒感染的Ｖｅｒｏ Ｅ６细胞,用抗糖蛋白单克隆抗体（ＨＣＯ２、     

单纯疱疹病毒2gD-Hsp70融合蛋白基因的构建及表达

构建并原核表达Hsp70-HSV2gD融合蛋白。将Hsp70和HSV-2gD蛋白基因分别克隆到原核表达载体pGEX-4T-1,构建成重组质粒pGEX-4T-Hsp70-gD,并测序鉴定。重组质粒pGEX-4T-Hsp70-gD转化大肠杆菌DH5α后,IPTG诱导表达并进行SDS-PAGE分析。表达产物纯化后做Westernblot检测。将其肌注免疫BALB/c小鼠,检测融合蛋白对免疫小鼠脾淋巴细胞增殖、γ-干扰素产生以及血清中gDIgG水平的影响。表达产物的SDS-PAGE分析发现,在相对分子量为118kD处有外源蛋白表达,与预期蛋白带一致。用GST柱得到了纯化的Hsp70-HSV2gD融合蛋白。Westernblot证实,表达产物具有良好的活性。GST-Hsp70-gD组蛋白疫苗免疫的小鼠,其脾淋巴细胞刺激指数和脾淋巴细胞培养上清中γ-干扰素的水平高于其它组(P<0.05)。血清单纯疱疹病毒-2gD蛋白的抗体水平高于其它组(P<0.05)。     

HSV-1溶瘤病毒的研究进展

1型单纯疱疹病毒（Herpes simplex virustype1,HSV-1）感染效率高且易于通过基因工程改造,己广泛应用于肿瘤治疗研究和临床实验。溶瘤HSV-1可通过基因工程改造或从HSV-1自发突变株中筛选获得。研究证实溶瘤HSV-1能够有效抑杀肿瘤细胞,可通过多种机制靶向肿瘤细胞,溶瘤HSV-1与放化疗联合使用治疗肿瘤的研究也取得了理想的结果。目前,已有多个溶瘤HSV-1进入临床试验。     

商陆蛋白质的纯化及其抗单纯疱疹病毒(Ⅱ型)活性的研究

纯化的商陆蛋白质Ⅰ在SDS-聚丙烯酰胺凝胶电泳中,只显示一条带,与Sigma SDS-6H四种蛋白质标准品迁移率对比,分子量大约为29,000。采用病毒繁殖量抑制测定法(YR测定),观察商陆蛋白质Ⅰ对疱疹病毒Ⅱ型(HSV-2)在Vero细胞中复制的影响,0.15～15μM出现最大抑制率,50％繁殖抑制率为0.32μM。证明商陆蛋白质Ⅰ对HSV-2有明显的抗病毒活性。     

Trichosanthin affects HSV-1 replication in Hep-2 cells

Trichosanthin (TCS) is a type I ribosome-inactivating protein that inhibits the replication of both human immunodeficiency virus type 1 (HIV-1) and herpes simplex virus type 1 (HSV-1). The mechanism of inhibition is not clear. This investigation explored the effects of TCS on the stages of HSV-1 infection in Hep-2 cells, from attachment to release. We demonstrated that TCS reduced HSV-1 antigen and DNA content and interfered with viral replication as early as 3-15 h after infection. TCS had no effect on HSV-1 attachment, penetration or immediate-early gene expression. However, the expression of early and late genes and virion release were diminished. In summary, this study demonstrates that TCS primarily affects HSV-1 replication in Hep-2 cells during the early to late infection period.     

Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease

To date, no vaccine that is safe and effective against herpes simplex virus 2 (HSV-2) disease has been licensed. In this study, we evaluated a DNA prime-formalin-inactivated-HSV-2 (FI-HSV2) boost vaccine approach in the guinea pig model of acute and recurrent HSV-2 genital disease. Five groups of guinea pigs were immunized and intravaginally challenged with HSV-2. Two groups were primed with plasmid DNAs encoding the secreted form of glycoprotein D2 (gD2t) together with two genes required for viral replication, either the helicase (UL5) and DNA polymerase (UL30) genes or the single-stranded DNA binding protein (UL29) and primase (UL52) genes. Both DNA-primed groups were boosted with FI-HSV2 formulated with monophosphoryl lipid A (MPL) and alum adjuvants. Two additional groups were primed with the empty backbone plasmid DNA (pVAX). These two groups were boosted with MPL and alum (MPL-alum) together with either formalin-inactivated mock HSV-2 (FI-Mock) or with FI-HSV2. The final group was immunized with gD2t protein in MPL-alum. After challenge, 0/9 animals in the group primed with UL5, UL30, and gD2t DNAs and all 10 animals in the mock-immunized control group (pVAX-FI-Mock) developed primary lesions. All mock controls developed recurrent lesions through day 100 postchallenge. Only 1 guinea pig in the group primed with pVAX DNA and boosted with FI-HSV2 (pVAX-FI-HSV2 group) and 2 guinea pigs in the group primed with UL5, UL30, and gD2t DNAs and boosted with FI-HSV2 (UL5, UL30, gD2t DNA-FI-HSV2 group) developed recurrent lesions. Strikingly, the UL5, UL30, gD2t DNA-FI-HSV2 group showed a 97% reduction in recurrent lesion days compared with the mock controls, had the highest reduction in days with recurrent disease, and contained the lowest mean HSV-2 DNA load in the dorsal root ganglia.     

2型单纯疱疹病毒毒力蛋白ICP34.5的真核表达及其对Ve-ro细胞活性的影响

目的:在非洲绿猴肾细胞(Vero细胞)中表达2型单纯疱疹病毒(HSV-2)毒力蛋白感染细胞多肽34.5(ICP34.5),并检测其对Vero细胞活性的影响。方法:PCR扩增HSV-2的ICP34.5基因,连接至pEGFP-C2载体,并对重组真核表达载体pEGFP-ICP34.5进行双酶切测序验证;将重组子瞬时转染Vero细胞,RT-PCR检测其在mRNA水平的表达,荧光倒置显微镜观察融合蛋白的表达,MTT法检测细胞活性。结果:经双酶切和测序验证表明pEGFP-ICP34.5构建成功,转染细胞后经RT-PCR验证有目的基因的转录,荧光显微镜下观察到融合蛋白在转染的Vero细胞中表达,MTT法检测结果证实重组质粒可以抵消空质粒对细胞的损伤作用。结论:构建了pEGFP-ICP34.5真核表达载体,其能在Vero细胞中高效表达,并能抵消空质粒对细胞的损伤作用。     

Modeling the synergy between HSV-2 and HIV and potential impact of HSV-2 therapy

Mounting evidence indicates that genital HSV-2 infection may increase susceptibility to HIV infection and that co-infection may increase infectiousness. Accordingly, antiviral treatment of people with HSV-2 may mitigate the incidence of HIV in populations where both pathogens occur. To better understand the epidemiological synergy between HIV and HSV-2, we formulate a deterministic compartmental model that describes the transmission dynamics of these pathogens. Unlike earlier models, ours incorporates gender and heterogeneous mixing between activity groups. We derive explicit expressions for the reproduction numbers of HSV-2 and HIV, as well as the invasion reproduction numbers via next generation matrices. A qualitative analysis of the system includes the local and global behavior of the model. Simulations reinforce these analytical results and demonstrate epidemiological synergy between HSV-2 and HIV. In particular, numerical results show that HSV-2 favors the invasion of HIV, may dramatically increase the peak as well as reducing the time-to-peak of HIV prevalence, and almost certainly has exacerbated HIV epidemics. The potential population-level impact of HSV-2 on HIV is demonstrated by calculating the fraction of HIV infections attributable to HSV-2 and the difference between HIV prevalence in the presence and absence of HSV-2. The potential impact of treating people with HSV-2 on HIV control is demonstrated by comparing HIV prevalence with and without HSV-2 therapy. Most importantly, we illustrate that the aforementioned aspects of the population dynamics can be significantly influenced by the sexual structure of the population.     

Dynamic Modeling of Herpes Simplex Virus Type-2 (HSV-2) Transmission: Issues in Structural Uncertainty

The sexually transmitted infection (STI) Herpes simplex virus type-2 (HSV-2) is of public health concern because it is a very common frequently unrecognized lifelong infection, which may facilitate HIV transmission. Within HIV/STI modeling, structural uncertainty has received less attention than parametric uncertainty. By merging the compartments of a “complex” model, a “simple” HSV-2 model is developed. Sexual interactions between female sex workers (FSWs) and clients are modeled using data from India. Latin Hypercube Sampling selects from parameter distributions and both models are run for each of the 10,000 parameter sets generated. Outputs are compared (except for 2,450 unrealistic simulations). The simple model is a good approximation to the complex model once the HSV-2 epidemic has reached 60% of the equilibrium prevalence (95% of the 7,550 runs produced <10% relative error). The simple model is a reduced version of the complex model that retains details implicitly. For late-stage epidemics, the simple model gives similar prevalence trends to the complex model. As HSV-2 epidemics in many populations are advanced, the simple model is accurate in most instances, although the complex model may be preferable for early epidemics. The analysis highlights the issue of structural uncertainty and the value of reducing complexity.     

青蒿提取物抗单纯疱疹病毒活性研究

用细胞病变效应(CPE)法证明了青蒿水提物具有抗单纯疱疹病毒Ⅱ型(HSV—2)活性,通过初步分离纯化得到抗HSV—2活性的有效成分。用MTT法研究了青蒿水提物和有效成分的细胞毒性和抗HSV—2活性,CC50分别为5．29mg／ml和4,94mg／ml,IC50分别为1．45mg／ml和0．128mg／ml,TI分别为3．65和38．6。以0．5mg／ml的无环鸟苷(ACV)作为阳性对照,结果显示有效成分在体外可以明显抑制HSV—2的致细胞病变作用,效果与ACV相当。     

Identification of an HSV-1/HSV-2 cross-reactive T cell determinant.

The results from a number of studies have documented that the HSV glycoprotein gD is an important target for neutralizing antibodies. In contrast, little is known about the Th cell determinants present on HSV that are required for anti HSV gD antibody production. In our study we have immunized BALB/c mice with a recombinant source of HSV-1 gD lacking the carboxyl-terminal 93 amino acids. T cell hybridomas produced from the immunized animals recognized a single antigenic peptide (amino acids 246-261) in the context of I-Ad. The determinant expressed by gD peptide 246-261 was generated and presented by both HSV-1 and HSV-2 infected APC. Fine specificity analysis using truncated synthetic gD peptides revealed that the minimal amino acids recognized by the T hybrids were identical between HSV-1 and HSV-2. In addition, the minimal peptide-I-Ad binding analysis demonstrated that the minimal peptide sequence required for the binding to I-Ad and for T cell recognition contained two prolines. Thus, this important HSV antigenic determinant would not be expected to form an amphipathic alpha-helix and could therefore be missed by algorithms currently used to predict which amino acid sequences would be antigenic based on the propensity to form helices.